



WHO Model List of Essential Medicines

Lorenzo Moja, MD, MSc, PhD, Dr Public Health
Secretariat of the Expert Committee on Selection and Use of Essential Medicines
Health Products and Standard Department, WHO HQ
mojal@who.int

WHO Model Lists of Essential Medicines





- First published in 1977, containing 208 medicines
- Introduced the idea that “some medicines are more important than others”
- Complemented in 2007 by the Model List of Essential Medicines for Children
- In 2023: 502 and 361 medicines on EML and EMLc, respectively
- Update growth rate: 3.6% per biennium
- Next update in May 2025



The WHO Model Lists

The primary purpose of the WHO Model Lists is to provide a blueprint for national authorities to adopt or adapt in accordance with local priorities and treatment guidelines for the development and updating of national EMLs.

NUMBER OF DIFFERENCES BETWEEN EACH COUNTRY'S LIST AND THE WHO'S MODEL LIST OF ESSENTIAL MEDICINES



<https://iris.who.int/handle/10665/330898>

Highlights from 2023 EML update

Cladribine, glatiramer acetate and rituximab for multiple sclerosis

Levetiracetam for focal-onset and generalized-onset seizures in adults in children

Ceftolozane + tazobactam as Reserve group antibiotic

Ravidasvir for hepatitis C

Monoclonal antibodies ansumvimab and atoltivimab + maftivimab + odesivimab for Ebola virus disease

Ready-to-use therapeutic food (RUTF) for severe acute malnutrition

Polypill current square box listings for hydrochlorothiazide, antihypertensives and statins

Donezipil for dementia due to Alzheimer disease (limited benefit)

Risdiplam for spinal muscular atrophy (immature data, high price)

GLP-1 for obesity (immature data, variable price)

PD-1/PD-L1 immune checkpoint inhibitors for non-small-cell lung cancer (high price, feasibility)

Cyclin-dependent kinase 4/6 inhibitors hormone receptor positive/HER2-negative advanced or metastatic breast cancer (immature data, high price)

CD-19-directed antigen receptor (CAR) T-cells for B-cell lymphoma (immature data, high price)

Osimertinib for EGFR-mutated non-small-cell lung cancer (immature data, high price, alternatives listed)

2025 EML update

- Application period closed on **1 November 2024**
- Applications to be published on the WHO website for comments on **1 February 2025**
- Meeting of the Expert Committee on Selection and Use of Essential Medicines from **5-9 May 2025**
- **Release of updated EML in July/August 2025**
 - (implications of EML recommendations for future EDL updates communicated to EDL Secretariat)

Updating the WHO Model Lists




Governance

Regulations for expert advisory panels and committees
Rules of procedure for expert committees
Reported as part of WHO's Technical Report Series




Procedures

- Revised in 2001 and endorsed by the Executive Board (EB109/8)



<https://apps.who.int/gb/bd/>



https://apps.who.int/gb/ebwha/pdf_files/EB109/eeb1098.pdf

The medicines landscape is becoming increasingly complex

The application process focused on single medicines makes it difficult to get a holistic picture especially in areas without dedicated WHO technical teams / guidelines

Many medicines included on the Model Lists do not have corresponding WHO guidelines covering their use

The quality of the applications is varying, some applications are incomplete and / or contain misleading information

The role of the EML regarding products that are not classic medicines

The role of the Model Lists in public health emergencies needs to be better defined

Thank you

For more information, please contact:

WHO Essential Medicines Team
Department of Health Products Policy & Standards

Lorenzo Moja – mojal@who.int
Bernadette Cappello – cappellob@who.int
EML Secretariat – emlsecretariat@who.int

